<DOC>
	<DOCNO>NCT01185548</DOCNO>
	<brief_summary>The purpose study assess effect tasisulam inhibitor CYP2C9 , use tolbutamide probe substrate . This study comprise three treatment period , continue access extension period . Period 1 4 day length . Periods 2 3 approximately 28 day length .</brief_summary>
	<brief_title>A Drug Interaction Study Tasisulam Patients With Advanced Cancer Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Tolbutamide</mesh_term>
	<criteria>1 . Have histologically cytologically confirm solid malignancy lymphoma advance and/or metastatic disease respond standard therapy standard therapy exist . 2 . Have give write informed consent prior studyspecific procedure . 3 . Have performance status less equal 1 Eastern Cooperative Oncology Group ( ECOG ) scale estimate life expectancy great 12 week . 4 . Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy , investigational therapy least 30 day ( 45 day mitomycinC nitrosoureas ) prior study enrollment recover acute effect therapy . Limited field radiotherapy permit ( consultation investigator ) . 5 . Have adequate organ function . 6 . Are reliable willing make available duration study willing follow study procedure . 7 . Males female reproductive potential must agree use medically approve contraceptive precaution trial 6 month follow last dose study drug . 8 . Females childbearing potential must negative serum pregnancy test le 7 day prior first dose study drug . 1 . Have receive treatment within 30 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication . 2 . Have know allergy tasisulam related compound . 3 . Have serious preexist medical condition . 4 . Show evidence significant active neuropsychiatric disease central nervous system ( CNS ) disease ( example , Alzheimer 's disease Parkinson 's disease ) . Patients active brain metastasis exclude . 5 . Have current acute chronic leukemia . 6 . Females pregnant lactating . 7 . Have know positive test result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) . 8 . History severe allergy multiple adverse drug reaction . 9 . Are person previously complete withdrawn study study investigate tasisulam . 10 . Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study . 11 . Serious concomitant systemic disorder , include diabetes active infection , incompatible study . 12 . Clinically significant cardiac symptomology . 13 . Patients treat warfarin . 14 . Patients treat sulfonylureas 15 . Regularly use drug abuse and/or show positive finding urinary drug screen accordance known/acceptable concomitant medication . 16 . Patients receive medication know inducer inhibitor CYP2C9 within 30 day prior enrollment . 17 . Have donate lose blood 500 mL within last month . 18 . Have average weekly alcohol intake exceed 21 unit per week ( male age 65 ) 14 unit per week ( male 65 female ) ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . 19 . Failure reason satisfy investigator adequate fitness participate study . 20 . Screening albumin level less 30 g/L .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Advanced Metastatic Solid Tumors Lymphoma</keyword>
</DOC>